The following is a summary of "Clinicopathologic and genomic analyses of SMARCA4-mutated non-small cell lung carcinoma ...

The updated guidelines note that patients with stage IV NSCLC who have EGFR exon 19 deletions or exon 21 L858R substitutions can receive osimertinib plus platinum doublet chemotherapy or amivantamab ...

If your non-small cell lung cancer (NSCLC) involves a gene mutation, you may receive a targeted therapy. These medications address specific gene mutations more effectively than standard cancer ...

A new systemic nutrition-inflammation index predicted perioperative non-small cell lung cancer outcomes better than current ...

In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that ...

During a live event, Alexander I. Spira, MD, PhD, and participants discuss efficacy, adverse events, and sequencing of EGFR-mutated NSCLC treatments.

A multivariate analysis confirmed the independent prognostic significance of both landmark and longitudinal MRD.

The FDA granted its first approval for a systemic therapy for patients with non-small cell lung cancer with an Neuregulin 1 ...

TEPMETKO is a kinase inhibitor prescribed for adult patients with metastatic non-small cell lung cancer (NSCLC) carrying MET exon 14 skipping alterations. The active component is Tepotinib (as ...

Microbio Co., Ltd. (TPEx: 4128) today announced promising results from an exploratory clinical trial assessing MS-20 in ...